Abstract: Embodiments include a package for containing and dispensing a product. The package includes first and second layers; a product seal zone where the first layer is joined to the second layer, the product seal zone having an inner perimeter that defines an unsealed pouch area for containing the product and an outer perimeter; and a header zone adjacent to the outer perimeter of the product seal zone. The header zone includes a first tab; a second tab; a first tab-cut in the first layer within an unsealed portion of the header zone; and a second tab-cut in the second layer within the unsealed portion of the header zone. Other embodiments are also included herein.
Type:
Grant
Filed:
September 23, 2020
Date of Patent:
April 26, 2022
Assignee:
Sunovion Pharmaceuticals Inc.
Inventors:
Julie A. Cardin, Edward Emmett Chapdelaine, Steven A. Rau
Abstract: The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
Type:
Application
Filed:
June 15, 2021
Publication date:
March 31, 2022
Applicant:
Sunovion Pharmaceuticals Inc.
Inventors:
Nandkumar Nivritti BHOGLE, Takahiko HASHIZUKA, Robert Joseph PRYTKO, John R. SNOONIAN, Harold Scott WILKINSON, Haitao ZHANG
Abstract: Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.
Abstract: Provided herein are methods of treating central nervous system (CNS) disorders (e.g., Binge Eating Disorder (BED), Attention-Deficit/Hyperactivity Disorder (ADHD), etc.) with a dasotraline therapy while avoiding adverse drug interactions.
Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
Type:
Grant
Filed:
May 6, 2019
Date of Patent:
December 7, 2021
Assignees:
Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
Inventors:
Linghong Xie, Philip Glyn Jones, Kerry L. Spear, Noel Aaron Powell, Taleen G. Hanania, Vadim Alexandrov
Abstract: Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.
Type:
Grant
Filed:
August 4, 2016
Date of Patent:
November 30, 2021
Assignee:
Sunovion Pharmaceuticals Inc.
Inventors:
Michele L. R. Heffernan, Larry Wendell Hardy, Scott P. Brown, Lee W. Herman
Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.
Abstract: The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
Type:
Grant
Filed:
March 13, 2020
Date of Patent:
October 5, 2021
Assignee:
Sunovion Pharmaceuticals Inc.
Inventors:
Nandkumar Nivritti Bhogle, Takahiko Hashizuka, Robert Joseph Prytko, John R. Snoonian, Harold Scott Wilkinson, Haitao Zhang
Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Ring B, A1, A2, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
Type:
Application
Filed:
February 19, 2021
Publication date:
September 30, 2021
Applicants:
Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
Inventors:
Milan CHYTIL, Sharon ENGEL, Taleen G. HANANIA, Vadim ALEXANDROV, Emer LEAHY
Abstract: Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.
Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
Type:
Application
Filed:
November 19, 2020
Publication date:
September 2, 2021
Applicants:
Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
Inventors:
Liming SHAO, John Emmerson CAMPBELL, Michael Charles HEWITT, Una CAMPBELL, Taleen G. HANANIA
Abstract: Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need thereof are also disclosed.
Type:
Grant
Filed:
July 28, 2017
Date of Patent:
August 3, 2021
Assignees:
Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
Inventors:
Vadim Alexandrov, Carrie A. Bowen, Taleen G. Hanania, Noel Aaron Powell
Abstract: The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
Type:
Grant
Filed:
March 13, 2020
Date of Patent:
July 20, 2021
Assignee:
Sunovion Pharmaceuticals Inc.
Inventors:
Nandkumar Nivritti Bhogle, Takahiko Hashizuka, Robert Joseph Prytko, John R. Snoonian, Harold Scott Wilkinson, Haitao Zhang
Abstract: Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.
Type:
Application
Filed:
August 12, 2020
Publication date:
April 1, 2021
Applicants:
Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
Inventors:
Carrie A. Bowen, Douglas F. Burdi, Michele L. R. Heffernan, Lee W. Herman, Linghong Xie
Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.
Type:
Grant
Filed:
September 9, 2019
Date of Patent:
March 30, 2021
Assignee:
Sunovion Pharmaceuticals Inc.
Inventors:
Scott David Barnhart, Michael Clinton Koons, Madhu Sudan Hariharan, Jordan Dubow, Thierry Bilbault, Anthony John Giovinazzo
Abstract: The various aspects present inventions provide various crystalline forms of (S)-(?)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.
Type:
Application
Filed:
August 17, 2020
Publication date:
March 4, 2021
Applicant:
Sunovion Pharmaceuticals Inc.
Inventors:
John R. Snoonian, Harold Scott Wilkinson, Haitao Zhang
Abstract: Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.
Type:
Application
Filed:
August 28, 2020
Publication date:
February 25, 2021
Applicant:
Sunovion Pharmaceuticals Inc.
Inventors:
Andrea BAUER, Nandkumar Nivritti BHOGLE, Xiaoxia CHEN, Shahla JAMZAD, Robert Joseph PRYTKO, Kostas SARANTEAS, Michael Joseph SIZENSKY, Harold Scott WILKINSON, Haitao ZHANG
Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.
Type:
Grant
Filed:
December 10, 2018
Date of Patent:
February 23, 2021
Assignees:
Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
Inventors:
Linghong Xie, Michele L. R. Heffernan, Philip Glyn Jones, Taleen G. Hanania
Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
Type:
Application
Filed:
June 2, 2020
Publication date:
February 18, 2021
Applicant:
SUNOVION PHARMACEUTICALS INC.
Inventors:
Thomas JERUSSI, Qun Kevin FANG, Mark G. CURRIE
Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
Type:
Grant
Filed:
February 14, 2020
Date of Patent:
January 19, 2021
Assignees:
Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
Inventors:
Liming Shao, John Emmerson Campbell, Michael Charles Hewitt, Una Campbell, Taleen G. Hanania